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ABSTRACT 
In this study, we investigated whether oxidative stress contributes to activation of kynurenine pathway by platinum nanoparticles 
(PtNPs). Thirty male Wistar rats with an average weight between 126 – 130 g were randomly assigned into six groups. The negative 
control group was orally administered distilled water while the other treatment groups respectively received oral administration of either 
PtNPs (25 and 50 mg/kg bw) singly or in combination with ascorbic acid (100 mg/kg bw). Results revealed that oral administration of 
PtNPs did not cause lipid peroxidation in rat brain and plasma relative to negative control. In contrast, PtNPs elevated protein carbonyl 
levels in rat plasma relative to negative control. In the meantime, the level of reduced glutathione (GSH) in rat tissues was maintained 
when compared with negative control and PtNPs alone. However, plasma GSH was significantly (p<0.05) increased by PtNPs at both 
doses used and co-treatment with ascorbic acid. Oral exposure to PtNPs and ascorbic acid elevated kynurenine level in rat plasma. Taken 
together, data indicated that PtNPs given alone at the doses investigated might not have caused oxidative stress in rat tissues and plasma 
but co-treatment with ascorbic acid appeared to potentiate capacity to elevate oxidative stress markers. Further, elevation of kynurenine 
level in rat plasma by PtNPs might be connected with oxidative stress since PtNPs did elevate protein carbonyl level and co-treatment 
with ascorbic acid modulated the kynurenine level.  
Keywords: Antioxidant; Nanoparticles; Oxidative stress; Tryptophan degradation. 
1. INTRODUCTION 
 The use of nanoparticles and nanomaterial is globally 
expanding. Nanoparticles have several applications in 
biomedicine; drug delivery, cellular delivery, cellular imaging, 
fluorescence imaging, antimicrobial potential [1-3]. Platinum and 
silver nanoparticles are among inorganic nanoparticles that are 
well investigated. For example, the silver nanoparticles have been 
reported for antimicrobial properties [1], while the antioxidant 
properties of platinum nanoparticles alongside its application as 
theranostic agents particularly in cancer therapy have been 
reported [4]. 
 Small size and a large ratio of surface area to volume are 
unique characteristics of nanoparticles. These properties enhance 
reactivity and permit cellular uptake and interaction [5, 6] capable 
of causing oxidative stress and/or eliciting inflammatory response 
[7]. Reports have implicated nanoparticles in cellular injury 
attributable to their ability to produce reactive oxygen species 
(ROS) directly or indirectly [8]. Though, reports have 
demonstrated the capacity of nanoparticles to produce free radicals 
among which is ROS [9, 10], there is no comprehensive 
understanding of the consequence of nanoparticles at the cellular 
level. Recently, Adeyemi et al [11] suggests that metal 
nanoparticles may impact multiple cellular targets. Activation of 
kynurenine pathway was reported as one of them. Kynurenine is a 
product of tryptophan degradation. The oxidative degradation of 
tryptophan to kynurenine is catalyzed by the tryptophan 2,3 
deoxygenase (TDO) in the liver and/or indoleamine 2,3-
dioxygenase (IDO) in extrahepatic tissues. Kynurenine can cyclize 
to form quinolinate, which can further be converted to 
nicotinamide adenine dinucleotide (NAD+). Investigations have 
shown that oxidative stress, a result of ROS production can affect 
immune behavior and neurotransmission levels thereby affecting 
neurotransmitter synthesis [12, 13]. Free radicals can stimulate the 
adaptive immune response giving rise to an appreciable impact on 
tryptophan oxidation. If there is an elevated level of pro-
inflammatory cytokines, this can lead to increased activity of IDO 
thereby directing tryptophan into the production of kynurenine 
[13] and subsequently kynurenic acid, which is neuroprotective. 
However, kynurenic acid can further generate quinolinic acid, 
which is neurodegenerative. While reports have linked stress to 
activation of the kynurenine pathway [12, 13], we do not know 
whether nanoparticles affect kynurenine pathway activation 
through ROS production or not. Such knowledge would contribute 
to our understanding of the cellular mechanism of nanoparticles. 
Therefore, this study investigates the effect of nanoparticles on rat 
kynurenine pathway and its link with oxidative stress. 
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2. EXPERIMENTAL SECTION 
2.1. Chemical and reagents. Platinum nanoparticles (PtNPs), 
Trolox, kynurenine standard, Ehrlich reagent were products of 
Sigma-Aldrich (St. Louis, MO, USA). All reagents were of 
analytical grade and used as supplied. 
2.2. Experimental animals. Thirty male Wistar rats with an 
average weight of 126 – 130 g were used in this study. Rats were 
obtained from the Department of Biochemistry, University of 
Ilorin, Ilorin, Nigeria, were kept in plastic cages in well aerated 
atmosphere and acclimated for two weeks before commencement 
of the study. Rats were given free access to commercial rat pellet 
and clean water ad libitum. 
 Handling of animals was humane and consistent with the 
International Guiding Principles for Biomedical Research 
Involving Animals. Geneva, Switzerland: (CIOMS, 1985), under 
the observation of the local Institutional Ethics Committee on 
Scientific Research with approval and protocol 20032018.  
2.3. Animal grouping and treatment protocol. The animals were 
randomly distributed into six (6) groups of five (5) rats in each 
group. The rats were given the oral administration of PtNPs singly 
or in combination with ascorbic acid. Further details of the 
treatment protocols are;  
Negative control: Administered 1 ml of distilled water. 
PtNPs 25 mg/kg: Administered PtNPs at 25 mg/kg bw only. 
PtNPs 50 mg/kg: Administered PtNPs at 50 mg/kg bw only. 
PtNPs 25 mg/kg + ASCO: Administered PtNPs (25 mg/kg bw) 
plus Ascorbic acid (100 mg/kg bw). 
PtNPs 50 mg/kg + ASCO: Administered PtNPs (50 mg/kg bw) 
plus Ascorbic acid (100 mg/kg bw). 
ASCO 100 mg/kg: Administered Ascorbic acid (100 mg/kg bw) 
only. 
Platinum nanoparticles were prepared in distilled water and the 
treatment was daily for seven days. Selection of doses was 
premised on previous studies [14]. 
2.4. Preparation of plasma and tissue homogenates. After the 
last treatment, rats were fasted overnight and sacrificed under mild 
anesthesia (diethyl ether). Blood samples from rats were collected 
in clean EDTA bottles and centrifuged at 5000 rpm (model C5, 
LW Scientific, GA, USA) for 10 min to obtain plasma which was 
collected in plain sample bottles and stored frozen until needed for 
analysis. The brain and liver samples were harvested, cleaned and 
homogenized in ice-cold 0.25M sucrose solution. The tissue 
homogenates were used for biochemical analysis.  
2.5. Biochemical assays. Biochemical measurements in rat 
plasma and tissue homogenates were carried out using a UV/Vis 
spectrophotometer (Jenway, Staffordshire, United Kingdom) 
where applicable. Total protein was determined according to the 
method of Gornall et al [15], protein carbonyl level was estimated 
by the method of Castegna et al [16] and malondialdehyde (MDA) 
as a byproduct of lipid peroxidation was determined as previously 
described by Varshney and Kale [17]. Kynurenine level was 
determined as reported elsewhere [11], reduced glutathione (GSH) 
level was determined by the method of Bentler et al [18] and the 
diphenylalanine (DPA) was used for the determination of DNA 
fragmentation according to the method of Perandones et al [19]. 
2.6. Statistical analysis. Data were analyzed using one-way 
ANOVA (GraphPad Software Inc., San Diego, CA, USA) and 
presented as mean value of five replicates ± standard error of the 
mean (SEM). Differences among the group mean values were 
analyzed by the Tukey’s post-hoc test. Mean values at p<0.05 
were taken as significant. 
 
3. RESULTS SECTION 
3.1. Average rat weight. Oral exposure to PtNPs either singly or 
in combination with ascorbic acid had no detectable effect on 
average rat weight (Fig. 1a and b). 
 
Fig. 1. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat average weight; [A] Before experimental treatments and [B] After 
experimental treatments. Each bar represents a mean value of four 
replicates ± standard error of the mean (SEM).  
3.2. Rat plasma and tissue total protein and kynurenine level. 
PtNPs at both doses decreased the total protein level of rat plasma 
when compared to negative control but not significantly. 
Combination of ascorbic acid with 50 mg/kg of PtNPs visibly 
raised the total protein level (Fig. 2a). ASCO alone likewise raised 
the protein level when compared with negative control. In rat 
liver, PtNPs at all doses used in this study had no effect on the 
protein level in comparison with negative control (Fig. 2b). 
However, the combination with ASCO caused a reduction in the 
protein level. ASCO alone also reduced the protein level when 
compared with the negative control group.  
 In rat brain, PtNPs at all doses used in this study reduced 
total protein level when compared with the control (Fig. 2c). This 
reduction was sustained even in combination with ASCO. In the 
meantime, level of kynurenine in rat plasma increased (p<0.05) 
following oral exposure to PtNPs (25 and 50 mg/kg bw) while co-
treatment with ascorbic acid maintained this increase in plasma 
kynurenine level (Fig. 3a). Ascorbic acid alone also increased the 
kynurenine level when compared to negative control. Oral 
exposure to PtNPs (25 and 50 mg/kg bw) as well as co-treatment 
with ascorbic acid had no appreciable effect on rat liver 
kynurenine level (Fig. 3b). However, ascorbic acid (100 mg/kg 
bw) alone elevated kynurenine level in rat liver when compared to 
negative control (Fig 3b). PtNPs treatment at 25 mg/kg bw did not 
affect rat brain kynurenine. However, the 50 mg/kg dose reduced 
the kynurenine level. In addition, co-treatment with ascorbic acid 
lowered kynurenine level compared with negative control (Fig. 
3c). 
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Fig. 2. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat total protein level; [A] Rat plasma, [B] Rat liver and [C] Rat brain. 
Each bar represents a mean value of four replicates ± standard error of the 
mean (SEM).  
 
Fig. 3. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat kynurenine level; [A] Rat plasma, [B] Rat liver and [C] Rat brain. 
Each bar represents a mean value of four replicates ± standard error of the 
mean (SEM). α is significant at p<0.05 versus negative control and γ at 
p<0.0001 versus negative control.  
 
3.3. Rat oxidative stress indices. In order to assess if PtNPs 
predisposes to oxidative stress, markers of oxidative stress such as 
protein carbonyl, malondialdehyde (MDA) and reduced 
glutathione (GSH) were assayed for. Results showed that oral 
administration of PtNPs led to a dose-dependent elevation of rat 
plasma protein carbonyl level (Fig. 4a) when compared to the 
negative control (p<0.05). Figure 4b and 4c revealed a significant 
decrease in protein carbonyl level in the liver and brain (Fig. 4b 
and c) especially at 50mg/kg dose of PtNPs. Co-treatment with 
ascorbic did not prevent this reduction. As a further measure of 
oxidative stress, MDA level as a byproduct of lipid peroxidation in 
rat tissues and plasma was determined after oral exposure to 
PtNPs. Results revealed that daily exposure to PtNPs as well as 
co-treatment with ascorbic acid did not alter MDA level when 
compared with negative control and PtNPs only respectively in the 
plasma (Fig. 5a). Lipid peroxidation as shown by the MDA level 
was increased by both PtNPs and co-treatment with ascorbic acid 
in the liver while it decreased in the brain (Fig. 5b and c). 
Meanwhile, ascorbic acid (100 mg/kg bw) alone caused an 
increase in MDA level of plasma and tissues. Furthermore, the 
level of reduced glutathione was determined in rat plasma and 
tissues. Results showed that oral treatment with PtNPs led to 
significant increases in GSH levels in rat plasma (Fig. 6a). In rat 
liver and brain, there were no significant changes in GSH level by 
PtNPs-treatment and ascorbic acid (Fig. 6b and c). 
3.4. Discussion. Oral administration of PtNPs as well as co-
treatment with ascorbic acid did not affect average rat weight. 
Likewise, oral exposure to PtNPs had no appreciable effect on rat 
tissue and plasma. Further, oral exposure to PtNPs might have 
caused mild oxidative stress in rat plasma and tissues; protein 
carbonyl in rat plasma increased while lipid peroxidation was 
elevated in rat brain and liver compared with negative control. The 
finding does not conform with the antioxidant property of PtNPs 
as reported elsewhere [14, 20, 21, 22]. 
 
Fig. 4. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat protein carbonyl level; [A] Rat plasma, [B] Rat liver and [C] Rat brain. 
Each bar represents a mean value of four replicates ± standard error of the 
mean (SEM). α is significant at p<0.05 versus negative control and/or 
PtNPs (50 mg/kg bw), β at p<0.001 versus negative control and/or PtNPs 
(25 mg/kg + ASCO and 50 mg/kg +ASCO), γ at p<0.0001 versus 
negative control. 
 
Fig. 5. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat malondialdehyde (MDA) level; [A] Rat plasma, [B] Rat liver and [C] 
Rat brain. Each bar represents a mean value of four replicates ± standard 
error of the mean (SEM). α is significant at p<0.05 versus negative 
control. 
 
Fig. 6. Effect of oral administration of platinum nanoparticles (PtNPs) on 
rat reduced glutathione (GSH) level; [A] Rat plasma, [B] Rat liver and 
[C] Rat brain. Each bar represents a mean value of four replicates ± 
standard error of the mean (SEM). α is significant at p<0.05 versus PtNPs 
(50 mg/kg bw + ASCO), β at p<0.001 versus PtNPs (25 mg/kg + ASCO), 
γ at p<0.0001 versus negative control and/or PtNPs (25 mg/kg + ASCO 
and 50 mg/kg + ASCO), µ at p<0.0001 versus negative control. 
 
Additionally, co-treatment with ascorbic acid raised rat plasma 
protein carbonyl level in manners that suggest potentiation of 
oxidative stress. It is possible that ascorbic acid and PtNPs 
interacts in ways that potentiate capacity to cause oxidative stress. 
According to Chen et al [23], PtNPs could interact with ascorbic 
acid blocking its antioxidant activity. Both PtNPs and ascorbic 
acid have antioxidant properties [22, 23], therefore, it is possible 
that the duo of PtNPs and ascorbic acid acted in a manner that 
neutralized their antioxidant potentials. More so, co-treatment with 
ascorbic acid also altered GSH levels. This may suggest usage of 
GSH molecules to combat ensuing oxidative stress. Additionally, 
the fact that oral exposure to PtNPs singly did not lower GSH 
levels may further underscore that ascorbic acid potentiated PtNPs 
to cause oxidative stress in rat tissues. Moreover, oral exposure to 
PtNPs elevated rat plasma kynurenine level and this elevation may 
be associated with oxidative stress viz-a-viz increased protein 
carbonyls. The finding supports and conforms with earlier 
investigations which linked oxidative stress to activation of 
kynurenine pathway [11, 12, 13, 24]. 
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4. CONCLUSIONS 
 In conclusion, findings herein revealed that oral exposure 
to PtNPs might have caused oxidative stress exclusively in rat 
plasma at the highest dose (50 mg/kg bw) used in this study. Also, 
the elevation of kynurenine level in rat plasma by PtNPs may be 
associated with capacity to cause oxidative stress. Additionally, 
data indicate that co-treatment with ascorbic acid potentiated 
PtNPs to cause oxidative stress in rat tissues which otherwise was 
not the case when PtNPs was administered singly. Together, 
findings contribute to deepening our understanding of the cellular 
interaction of nanoparticles. 
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